Telitacicept Improves Clinical Response in Active SLE
A 52-week trial of patients with active systemic lupus erythematosus (SLE) found that telitacicept produced a higher clinical response rate compared to placebo.
The study, published in the New England Journal of Medicine, evaluated the efficacy and safety of telitacicept, a dual B-cell activating factor (BAFF) and APRIL inhibitor.
- Patientes treated with telitacicept achieved significantly greater improvements in disease activity scores.
- The treatment resulted in better control of lupus manifestations such as rash, arthritis, and serologic activity.
However, the treatment was also linked to increased rates of upper respiratory infections, decreased immunoglobulin levels, and injection-site reactions.
The trial demonstrated that telitacicept’s mechanism—targeting both BAFF and APRIL pathways—effectively suppresses B-cell overactivation, a key driver of autoimmunity in SLE.
Author's summary: Telitacicept improves SLE response rates.
More News
- Dana Almassova Kazakhstan
- Miss Universe 2025
- Matthew Lillard Admits He Doesn’t Have “Huge Part” In ‘FNAF 2’, Teases Potential Trilogy Showdown
- Netflix, Inc. (NFLX) Stock Price, Quote, News & Analysis
- [Matthew Lillard Admits Quentin Tarantino Criticism]
- Why Netflix Shares Falling Today
- [Trump Berates Reporters, Gets Mystery MRI & Closes ...]
- [Dana Almassova Kazakhstan – пост Nikkei Asia]
- Netflix Inc. Stock Quote NFLX — MarketWatch data
- [DANA ALMASSOVA TikTok video 7579709068915395896]